Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

BTAIQ

BioXcel Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1720893Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$1.0M
Net Income FY2025
$(70.0M)
EPS (Basic, as reported)
$-5.73
Net Margin FY2025
-10887.4%
ROE FY2025
73.2%
Total Equity
$(95.0M)
Shares Out
31M
Business description

BioXcel Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 1
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023⚑FY2024⚑FY2025
Revenue—————0121
Cost of revenue—————0(1)(2)0
Research & development(3)(15)(26)(58)(53)(91)(84)(30)(30)
Selling, general & administrative————(54)(69)(83)(34)(20)
General & administrative(2)(5)(8)(24)(54)————
Total operating expenses(5)(20)(34)(82)(107)(160)(173)(70)(51)
Operating income(5)(20)(34)(82)(107)(160)(172)(67)(50)
Interest expense——000(8)(13)(15)(17)
Interest & investment income———003631
Other income (expense), net—————0020(4)
Income tax expense——————000
Net income(5)(19)(33)(82)(107)(166)(179)(60)(70)
EPS — basic———($3.79)($4.05)($5.92)($6.15)($23.51)($5.73)
EPS — diluted———($3.79)($4.05)($5.92)($6.15)($23.51)($5.73)
Shares outstanding — basic (M)———22262829312
Shares outstanding — diluted (M)———22262829312
  • ⚑ Weighted-average shares changed ÷10.00 between FY2023 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×4.00 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.